Skip to content
Log in
Sponsored Design Multi-Agent AI Systems Using MCP and A2A: Engineer your own Pyt Design Multi-Agent AI Systems Using MCP and A2A: Engineer your own Pyt
Open access

Prevalence of Treatment‐Resistant Schizophrenia: A Nationwide Multicenter Study

Yusuke Arai Toru Horinouchi Hiroyuki Muraoka J. Matsumoto Kazuhiko Yamamuro Toshinori Nakamura Hisashi Yamada Toshiaki Onitsuka Y. Yasuda Naoki Hashimoto K. Ohi Shinichiro Ochi Y. Kawamata Keisuke Mori Hirotaka Yamagata T. Tsuboi F. Kodaka J. Iga S. Numata Ken Inada Koichiro Watanabe Hikaru Hori N. Yasui-Furukori R. Hashimoto
Sep 2026 · Neuropsychopharmacology Reports · Vol 46 · 0 citations · 25 references
Medicine

TL;DR

The prevalence of treatment‐resistant schizophrenia (TRS) among patients with schizophrenia remains insufficiently characterized using nationwide data and standardized diagnostic criteria.

Abstract

Schizophrenia is characterized by positive symptoms, negative symptoms, and cognitive impairment and is primarily treated with antipsychotic medications. However, a subset of patients responds inadequately to treatment and is classified as having treatment‐resistant schizophrenia (TRS). The prevalence of TRS among patients with schizophrenia remains insufficiently characterized. This study aimed to determine the prevalence of TRS using nationwide data and standardized diagnostic criteria.

DOI PubMed Semantic Scholar
Read PDF

Similar papers

Open access Aug 2026

AJP authors propose broader definition of resistant schizophrenia

A proposal to expand the definition of treatment‐resistant schizophrenia (TRS) could help clinicians identify patients earlier and improve access to effective interventions, according to authors of new commentary published in the American Journal of Psychiatry (AJP). The authors argue that current definitions may not f...

Valerie A. Canady · 0 citations
Review Open access Sep 2026

Beyond Clozapine Failure: Precision Approach and Palliative Psychiatry in Ultra-Treatment-Resistant Schizophrenia

Clozapine is the only evidence-based treatment for treatment-resistant schizophrenia (TRS); however, up to 70% of patients have an inadequate response, leading to clozapine-resistant schizophrenia (CRS) and, in its most severe form, ultra-treatment-resistant schizophrenia (UTRS). Because evidence-based treatment algori...

M. Peraire, A. Moreno-Beltrán, Aitana Fillol et al. · 0 citations
Open access Sep 2026

Early intervention with clozapine: Is there a neurobiological critical period for treatment-resistant schizophrenia?

Clozapine is the most effective treatment for treatment-resistant schizophrenia, yet it is often introduced late. This article proposes a critical period hypothesis, arguing that clozapine is most effective when started during a stage of illness in which network plasticity and synaptic substrate are still partially pre...

R. Krishnadas, I. L. Leong, Joanna Fraczek et al. · 0 citations
Review Open access Sep 2026

856. Treatment-Resistant Schizophrenia: Definitions, Current Pharmacological Strategies, and Emerging Pipeline Therapies

Abstract Background Antipsychotic monotherapy is the guideline-supported mainstay of treatment for schizophrenia. However, approximately 40% of patients fail to achieve an adequate response in randomized controlled trials, highlighting the significant clinical challenge of treatment-resistant schizophrenia (TRS). Despi...

M. Samara · 0 citations
Review Open access Aug 2026

The Role of Glutamatergic and Dopaminergic Genes in Resistant Schizophrenia: A Systematic Review.

A systematic literature search was conducted across four databases utilizing the treatment response and resistance in psychosis criteria to standardize the definition of resistance, finding concordant genetic findings in key dopaminergic and glutamatergic pathways related to TRS.

M.T. Moreno-Calle, Silvia Iñiguez-Barrio, Maria Aurora Arrue et al. · 0 citations
Open access Sep 2026

Navigating clozapine discontinuation in clinical practice: An updated framework.

Clozapine remains the most effective treatment for treatment-resistant schizophrenia (TRS), yet clinicians are frequently faced with situations where discontinuation must be considered due to adverse effects, patient preference, or lack of effectiveness. This article proposes an eight-step, clinically informed approach...

Grace Charter, Nadezda Asceric, Prashant Tibrewal et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.